PL398491A1 - Diazabicykliczny związek (cis)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3,2,0]-heptan, środek do leczenia i ich zastosowanie - Google Patents

Diazabicykliczny związek (cis)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3,2,0]-heptan, środek do leczenia i ich zastosowanie

Info

Publication number
PL398491A1
PL398491A1 PL398491A PL39849101A PL398491A1 PL 398491 A1 PL398491 A1 PL 398491A1 PL 398491 A PL398491 A PL 398491A PL 39849101 A PL39849101 A PL 39849101A PL 398491 A1 PL398491 A1 PL 398491A1
Authority
PL
Poland
Prior art keywords
diazabicyclo
pyridinyl
dichloro
heptane
cis
Prior art date
Application number
PL398491A
Other languages
English (en)
Inventor
Michael R. Schrimpf
Karin R. Tietje
Richard B. Toupence
Jianguo Ji
Anwer Basha
William H. Bunnelle
Jerome F. Daanen
Jennifer M. Pace
Kevin B. Sippy
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of PL398491A1 publication Critical patent/PL398491A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL398491A 2000-04-27 2001-04-27 Diazabicykliczny związek (cis)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3,2,0]-heptan, środek do leczenia i ich zastosowanie PL398491A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents

Publications (1)

Publication Number Publication Date
PL398491A1 true PL398491A1 (pl) 2012-06-04

Family

ID=27072208

Family Applications (2)

Application Number Title Priority Date Filing Date
PL01358340A PL358340A1 (pl) 2000-04-27 2001-04-27 Diazabicykliczne środki aktywne wobec centralnegoukładu nerwowego
PL398491A PL398491A1 (pl) 2000-04-27 2001-04-27 Diazabicykliczny związek (cis)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3,2,0]-heptan, środek do leczenia i ich zastosowanie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL01358340A PL358340A1 (pl) 2000-04-27 2001-04-27 Diazabicykliczne środki aktywne wobec centralnegoukładu nerwowego

Country Status (22)

Country Link
EP (3) EP2295437A1 (pl)
JP (2) JP4981232B2 (pl)
KR (4) KR100947188B1 (pl)
CN (3) CN100430398C (pl)
AR (1) AR030421A1 (pl)
AU (2) AU6655901A (pl)
BG (2) BG66151B1 (pl)
BR (1) BR0107246A (pl)
CA (2) CA2683045A1 (pl)
CZ (4) CZ301324B6 (pl)
HK (1) HK1054375A1 (pl)
HU (1) HUP0300602A3 (pl)
IL (3) IL152231A0 (pl)
MX (1) MXPA02010594A (pl)
MY (3) MY145722A (pl)
NO (1) NO324250B1 (pl)
NZ (1) NZ521734A (pl)
PE (1) PE20011305A1 (pl)
PL (2) PL358340A1 (pl)
SK (2) SK287273B6 (pl)
TW (4) TWI357903B (pl)
WO (1) WO2001081347A2 (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
RS20050380A (sr) * 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
ES2391472T3 (es) * 2005-12-20 2012-11-27 Astrazeneca Ab Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2129672B1 (en) 2007-03-23 2011-05-18 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
CN101809021B (zh) 2007-09-11 2013-04-24 雅培制药有限公司 八氢-吡咯并[3,4-b]吡咯n-氧化物
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
MX2010005650A (es) * 2007-11-21 2010-06-02 Abbott Lab Derivados de diazabicicloalcano substituidos con biarilo.
NZ586651A (en) 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
ES2398676T3 (es) 2007-12-07 2013-03-20 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
JP5323088B2 (ja) 2007-12-18 2013-10-23 アクテリオン ファーマシューティカルズ リミテッド 5−アミノシクリルメチル−オキサゾリジン−2−オン誘導体
PT2268646E (pt) 2008-04-11 2013-12-10 Janssen Pharmaceutica Nv Aminas de tiazolopiridina-2-iloxi-fenil e de tiazolopirazina-2-iloxi-fenilo como moduladores da hidrolase de leucotrieno a4
US8148408B2 (en) * 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
CA2755810A1 (en) * 2009-03-24 2010-09-30 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
MX2011012190A (es) 2009-05-14 2011-12-08 Janssen Pharmaceutica Nv Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa.
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
US8268853B2 (en) 2009-06-25 2012-09-18 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ma公司 布魯頓氏酪胺酸激酶抑制劑
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
CA2964103C (en) 2014-10-31 2022-08-30 Indivior Uk Limited Dopamine d3 receptor antagonist compounds
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
CA3031443A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
WO2019057123A1 (zh) * 2017-09-20 2019-03-28 杭州英创医药科技有限公司 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
RS65638B1 (sr) 2018-11-14 2024-07-31 Janssen Pharmaceutica Nv Unapređene sintetičke metode pravljenja fuzionisanih heterocikličnih jedinjenja kao modulatora receptora oreksina
CN112010859B (zh) * 2019-05-30 2022-07-19 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
CN120097862A (zh) 2019-08-07 2025-06-06 詹森药业有限公司 制备作为食欲素受体调节剂的(2h-1,2,3-三唑-2-基)苯基化合物的改进的合成方法
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59009705D1 (de) 1989-04-17 1995-11-02 Bayer Ag Verfahren zur Herstellung von 2,7-Diazabicyclo(3.3.0)octanen.
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
CA2112165C (en) 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
DE69612292T2 (de) * 1995-07-28 2001-11-22 Abbott Laboratories, Abbott Park Furo-, thieno- und pyrrolopyridine und verwandte pyrinidin-, pyridazin- und triazinverbindungen verwendbar zur kontrolle von chemische synaptische übertragung
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
KR100589872B1 (ko) * 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
JP2002502383A (ja) * 1997-05-30 2002-01-22 ニューロサーアチ・アクティーゼルスカブ ニコチンAChレセプターに於けるコリン作動性リガンドとしての9−アザビシクロ(3.3.1)ノン−2−エン及びノナン誘導体
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
KR100607838B1 (ko) * 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
BR9907172A (pt) * 1998-04-02 2000-10-10 Reynolds Tobacco Co R Derivados de azatriciclo[3.3.1.1] decano e composições farmacêuticas contendo-os
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
EP1147112B1 (en) * 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
NZ513575A (en) * 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
ES2226844T3 (es) * 1999-05-21 2005-04-01 Abbott Laboratories Aminoazaciclos heterociclicos sustituidos utiles como agentes activos sobre el sistema nervioso central.
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.

Also Published As

Publication number Publication date
BR0107246A (pt) 2002-10-01
KR20090121385A (ko) 2009-11-25
MY145722A (en) 2012-03-30
NO20025107D0 (no) 2002-10-24
CA2683045A1 (en) 2001-11-01
NO20025107L (no) 2002-12-19
TWI311137B (en) 2009-06-21
HUP0300602A2 (hu) 2003-06-28
AR030421A1 (es) 2003-08-20
BG107303A (bg) 2003-07-31
MY137020A (en) 2008-12-31
IL152231A0 (en) 2003-05-29
CZ20023765A3 (cs) 2003-02-12
EP1284976A2 (en) 2003-02-26
CN101935322A (zh) 2011-01-05
KR20090071654A (ko) 2009-07-01
AU2001266559B2 (en) 2005-03-03
KR20020093955A (ko) 2002-12-16
BG66151B1 (bg) 2011-08-31
HK1054375A1 (zh) 2003-11-28
TW200617013A (en) 2006-06-01
NZ521734A (en) 2004-10-29
MY168244A (en) 2018-10-15
BG110620A (bg) 2010-07-30
AU2001266559C1 (en) 2005-11-17
IL177316A0 (en) 2006-12-10
TWI357903B (en) 2012-02-11
JP2012041349A (ja) 2012-03-01
TWI323733B (en) 2010-04-21
NO324250B1 (no) 2007-09-17
JP4981232B2 (ja) 2012-07-18
IL203035A (en) 2010-12-30
IL177316A (en) 2010-06-30
KR100899950B1 (ko) 2009-05-28
EP2295437A1 (en) 2011-03-16
KR100947187B1 (ko) 2010-03-12
TW200909432A (en) 2009-03-01
CN1440410A (zh) 2003-09-03
KR20090013833A (ko) 2009-02-05
SK16812002A3 (sk) 2003-04-01
CN100430398C (zh) 2008-11-05
SK287658B6 (sk) 2011-05-06
KR100961406B1 (ko) 2010-06-09
CZ302072B6 (cs) 2010-09-29
TW201141871A (en) 2011-12-01
CZ302795B6 (cs) 2011-11-16
MXPA02010594A (es) 2003-05-14
EP2298775A1 (en) 2011-03-23
KR100947188B1 (ko) 2010-03-12
WO2001081347A3 (en) 2002-01-31
AU6655901A (en) 2001-11-07
WO2001081347A2 (en) 2001-11-01
CN102863441A (zh) 2013-01-09
JP2003531210A (ja) 2003-10-21
CA2407094A1 (en) 2001-11-01
SK287273B6 (sk) 2010-05-07
CZ301324B6 (cs) 2010-01-13
PE20011305A1 (es) 2001-12-31
HUP0300602A3 (en) 2005-12-28
PL358340A1 (pl) 2004-08-09
CZ302038B6 (cs) 2010-09-15
CA2407094C (en) 2009-11-17

Similar Documents

Publication Publication Date Title
MXPA02002898A (es) Pirazolopirimidinas como agentes terapeuticos.
ZA200306886B (en) Pyrazolopyrimidines as therapeutic agents.
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
AU1393000A (en) 1,4-diazabicyclo(3.2.2)nonane derivatives, their preparation and therapeutic application
IL157640A0 (en) Pyrazolopyrimidines as therapeutic agents
IL152231A0 (en) Diazabicyclic central nervous system active agents
ZA200202519B (en) Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines.
GB0027561D0 (en) Therapeutic agents
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
PL349341A1 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives
PL349364A1 (en) Use of pyridazino[4,5-b
MXPA03008894A (es) Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.
ZA200110046B (en) Therapeutic agents.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
GB2334672B (en) The Allenderry chair
SI1212327T1 (en) Pyrazolopyrimidines as therapeutic agents
ZA99132B (en) Therapeutic agents.
ZA200204584B (en) Therapeutic agents.
PL352760A1 (pl) Oksatiepino [6,5-b] dihydropirydyny, zawierające je kompozycje oraz sposoby wytwarzania
GB9920599D0 (en) The body seat
TW398311U (en) Illuminant inter-hit balls
TW386454U (en) The fitness equipment for sit/lie dual use
TW407477U (en) Multi-purpose chair structure
TW343509U (en) Multi-purpose cup
GB9910914D0 (en) The chair

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)